MA30153B1 - Anticorps anti-ox40l et methodes correspondantes - Google Patents

Anticorps anti-ox40l et methodes correspondantes

Info

Publication number
MA30153B1
MA30153B1 MA31104A MA31104A MA30153B1 MA 30153 B1 MA30153 B1 MA 30153B1 MA 31104 A MA31104 A MA 31104A MA 31104 A MA31104 A MA 31104A MA 30153 B1 MA30153 B1 MA 30153B1
Authority
MA
Morocco
Prior art keywords
corresponding methods
ox40l antibodies
ox40l
antibodies
methods
Prior art date
Application number
MA31104A
Other languages
English (en)
Inventor
Flavius Martin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA30153B1 publication Critical patent/MA30153B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention fournit des anticorps anti-OX40L, des compositions les comportant et méthodes correspondantes.
MA31104A 2005-12-16 2008-07-11 Anticorps anti-ox40l et methodes correspondantes MA30153B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75137705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
MA30153B1 true MA30153B1 (fr) 2009-01-02

Family

ID=38616368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31104A MA30153B1 (fr) 2005-12-16 2008-07-11 Anticorps anti-ox40l et methodes correspondantes

Country Status (18)

Country Link
US (2) US7812133B2 (fr)
EP (1) EP1973949A2 (fr)
JP (1) JP2009519718A (fr)
KR (1) KR20080080639A (fr)
CN (1) CN101374865A (fr)
AR (1) AR057253A1 (fr)
AU (1) AU2006343459A1 (fr)
BR (1) BRPI0621065A2 (fr)
CA (1) CA2633602A1 (fr)
CR (1) CR10069A (fr)
EC (1) ECSP088543A (fr)
IL (1) IL191820A0 (fr)
MA (1) MA30153B1 (fr)
NO (1) NO20083147L (fr)
RU (1) RU2426744C2 (fr)
TW (1) TW200732349A (fr)
WO (1) WO2007133290A2 (fr)
ZA (1) ZA200804868B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
JP5371142B2 (ja) 2006-07-14 2013-12-18 エフ・イ−・アイ・カンパニー マルチソース型のプラズマ集束イオン・ビーム・システム
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009141239A1 (fr) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
EP2513145B1 (fr) 2009-12-14 2018-01-24 Ablynx N.V. Domaines variables uniques de liaison anti-ox40l, construits et application therapeutique
US20120020960A1 (en) * 2010-07-26 2012-01-26 Baylor Research Institute Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer
SMT201700185T1 (it) 2010-08-23 2017-05-08 Univ Texas Anticorpi anti-ox40 e metodi di uso degli stessi
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
BR112013026828A2 (pt) 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
CA2845810C (fr) * 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procedes d'utilisation
US9657059B2 (en) * 2013-09-09 2017-05-23 Canimguide Therapeutics Ab Immune system modulators
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP2017165652A (ja) * 2014-06-30 2017-09-21 国立大学法人東北大学 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
CN107074951B (zh) * 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
MX2017011194A (es) * 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CA2978617A1 (fr) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Modulateurs et compositions du systeme immunitaire
CA2984794A1 (fr) 2015-05-07 2016-11-10 Agenus Inc. Anticorps anti-ox40 et procedes d'utilisation de ceux-ci
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
AU2016402264B2 (en) * 2016-04-15 2024-08-22 Pontificia Universidad Católica De Chile Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
KR102769109B1 (ko) 2017-11-24 2025-02-18 유큐(베이징) 바이오파마 코., 엘티디 항―ｏｘ４０ 항체 및 그의 용도
EP3728314A1 (fr) 2017-12-19 2020-10-28 Kymab Limited Anticorps bispécifique pour icos et pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
TWI905133B (zh) * 2020-12-09 2025-11-21 南韓商怡諾安有限公司 抗-OX40L抗體、抗OX40L和抗-TNFα雙特異性抗體及其用途
JP7688150B2 (ja) * 2020-12-09 2025-06-03 エイチケー イノ．エヌ コーポレーション 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
MX2024001877A (es) * 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
US20250340659A1 (en) * 2022-02-09 2025-11-06 PetMedix Ltd. Therapeutic antibodies
WO2025090570A1 (fr) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anticorps anti-ox40l et méthodes d'utilisation
TW202540204A (zh) * 2024-01-26 2025-10-16 西班牙商阿爾米雷爾有限公司 雙特異性分子及使用其的治療方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) * 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
WO2001094586A2 (fr) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Anticorps non agonistiques diriges contre gp 39 humaine, compositions les contenant et leur utilisation therapeutique
FR2822846B1 (fr) * 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
JP3926596B2 (ja) 2001-09-28 2007-06-06 独立行政法人科学技術振興機構 Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
AU2002365814A1 (en) * 2001-12-18 2003-07-30 J And J Research Pty Ltd Method of treating asthma
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
JP2006081061A (ja) * 2004-09-13 2006-03-23 Alpine Electronics Inc 音声出力装置及び音声／映像出力装置
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
ZA200804868B (en) 2009-10-28
WO2007133290A8 (fr) 2008-03-27
WO2007133290A3 (fr) 2008-01-10
IL191820A0 (en) 2008-12-29
EP1973949A2 (fr) 2008-10-01
US7812133B2 (en) 2010-10-12
TW200732349A (en) 2007-09-01
BRPI0621065A2 (pt) 2011-11-29
AR057253A1 (es) 2007-11-21
AU2006343459A1 (en) 2007-11-22
RU2008129111A (ru) 2010-01-27
CA2633602A1 (fr) 2007-11-22
CN101374865A (zh) 2009-02-25
NO20083147L (no) 2008-09-16
KR20080080639A (ko) 2008-09-04
US20100272738A1 (en) 2010-10-28
JP2009519718A (ja) 2009-05-21
WO2007133290A2 (fr) 2007-11-22
RU2426744C2 (ru) 2011-08-20
CR10069A (es) 2008-10-10
ECSP088543A (es) 2008-07-30
US20090053230A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
CY2018013I2 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EP1896073A4 (fr) Anticorps anti-il-23, compositions, méthodes et utilisations
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
EA200702643A1 (ru) Антитела, связывающие tweak
TW200626171A (en) Fixed dosing of HER antibodies
EA200701918A1 (ru) Белок липокалин
TW200709817A (en) Platform antibody compositions
DK1804589T3 (da) Fedtsammensætninger
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
EA200702193A1 (ru) Гликозилирование белков
ATE499341T1 (de) 5-(2,2-dimethyl-cyclopropyl)-3-methylpent-2- ennitril als geruchs- und geschmacksstoff
FR2894983B1 (fr) Test de caracterisation des anticorps.
WO2007073567A3 (fr) Compositions et procedes pour la modulation de la reponse immunitaire
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
WO2007002096A3 (fr) Methodes et compositions permettant de cibler ifnar2